4.4 Article

Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism

期刊

PSYCHOPHARMACOLOGY
卷 228, 期 1, 页码 157-166

出版社

SPRINGER
DOI: 10.1007/s00213-013-3024-x

关键词

Antidepressant; Behaviour; Depression; Forced swimming test; Ketamine; NMDA receptor; Serotonin

资金

  1. Health Research Board of Ireland

向作者/读者索取更多资源

Behavioural antidepressant-like effects of ketamine have been reported in the forced swimming test (FST). The mechanisms mediating such effects are unknown. As serotonin (5-HT) is an important transmitter mediating antidepressant responsiveness in the FST, the influence of 5-HT depletion on the antidepressant-like effect of ketamine was assessed. The effect of ketamine (25 mg/kg, i.p., 1 or 24 h prior to test) was assessed in the FST in naive rats or animals subjected to 5-HT depletion, repeated stress or following a combination of 5-HT depletion and stress. Endogenous 5-HT was depleted using the tryptophan hydroxylase inhibitor para-chlorophenylalanine (3 x 150 mg/kg, i.p.). Stress was induced by physical restraint (2 h/day for 10 days). In naive rats, ketamine administered 24 or 1 h prior to test produced a characteristic antidepressant-like reduction in immobility time in the FST. Depletion of 5-HT blocked this reduction in immobility when ketamine was administered 24 h prior FST, indicative of 5-HT dependency. The increase in immobility provoked by repeated restraint stress (2 h/day for 10 days) was blocked by ketamine when administered 24 h prior to FST, but this effect dissipated when animals were subjected to 5-HT depletion. These observations are consistent with a role for 5-HT in mediating sustained antidepressant activity of ketamine in the FST. Molecular and cellular changes induced by ketamine may produce a rapid adaptation of 5-HT transmission which underlies the antidepressant response.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemistry & Molecular Biology

Diurnal Hypothalamic-Pituitary-Adrenal Axis Measures and Inflammatory Marker Correlates in Major Depressive Disorder

Kelly Doolin, Chloe Farrell, Leonardo Tozzi, Andrew Harkin, Thomas Frodl, Veronica O'Keane

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)

Article Psychiatry

DNA methylation differences at the glucocorticoid receptor gene in depression are related to functional alterations in hypothalamic-pituitary-adrenal axis activity and to early life emotional abuse

Chloe Farrell, Kelly Doolin, Niamh O'Leary, Chaitra Jairaj, Darren Roddy, Leonardo Tozzi, Derek Morris, Andrew Harkin, Thomas Frodl, Zsofia Nemoda, Moshe Szyf, Linda Booij, Veronica O'Keane

PSYCHIATRY RESEARCH (2018)

Editorial Material Immunology

Ketamine and depression: A special kase for kynurenic acid?

Andrew Harkin, Declan M. McLoughlin

BRAIN BEHAVIOR AND IMMUNITY (2019)

Article Neurosciences

L-alpha-aminoadipic acid restricts dopaminergic neurodegeneration and motor deficits in an inflammatory model of Parkinson's disease in male rats

Eoin O'Neill, Rosa Chiara Goisis, Ruth Haverty, Andrew Harkin

JOURNAL OF NEUROSCIENCE RESEARCH (2019)

Article Behavioral Sciences

L-alpha-amino adipic acid provokes depression-like behaviour and a stress related increase in dendritic spine density in the pre-limbic cortex and hippocampus in rodents

J. David, S. Gormley, A. L. McIntosh, V. Kebede, G. Thuery, A. Varidaki, E. T. Coffey, A. Harkin

BEHAVIOURAL BRAIN RESEARCH (2019)

Article Biochemistry & Molecular Biology

Oxytocin Signaling in the Central Amygdala Modulates Emotion Discrimination in Mice

Valentina Ferretti, Federica Maltese, Gabriella Contarini, Marco Nigro, Alessandra Bonavia, Huiping Huang, Valentina Gigliucci, Giovanni Morelli, Diego Scheggia, Francesca Manago, Giulia Castellani, Arthur Lefevre, Laura Cancedda, Bice Chini, Valery Grinevich, Francesco Papaleo

CURRENT BIOLOGY (2019)

Article Pharmacology & Pharmacy

Pharmacological targeting of β2-adrenoceptors is neuroprotective in the LPS inflammatory rat model of Parkinson's disease

Eoin O'Neill, Justin D. Yssel, Caoimhe McNamara, Andrew Harkin

BRITISH JOURNAL OF PHARMACOLOGY (2020)

Article Behavioral Sciences

Impaired approach to novelty and striatal alterations in the oxytocin receptor deficient mouse model of autism

Marianna Leonzino, Luisa Ponzoni, Daniela Braida, Valentina Gigliucci, Marta Busnelli, Ilaria Ceresini, Natalia Duque-Wilckens, Katsuhiko Nishimori, Brian C. Trainor, Mariaelvina Sala, Bice Chini

HORMONES AND BEHAVIOR (2019)

Article Neurosciences

Kynurenic Acid Protects Against Reactive Glial-associated Reductions in the Complexity of Primary Cortical Neurons

Kate O'Reilly, Katherine O'Farrell, Oivind Midttun, Yuliia Rakovets, Jennifer David -Bercholz, Andrew Harkin

Summary: This study demonstrates that brain glia produce neuroactive metabolites via tryptophan-kynurenine catabolism and play a role in reactive glial associated neurodegeneration. Results suggest that inhibiting the kynurenine pathway (KP) metabolites can protect against neuronal atrophy associated with reactive glia.

JOURNAL OF NEUROIMMUNE PHARMACOLOGY (2021)

Article Clinical Neurology

PBMC telomerase activity in depression and the response to electroconvulsive therapy

Karen M. Ryan, Martha Finnegan, Andrew Harkin, Declan M. McLoughlin

Summary: The study found no significant association between telomerase activity and depression, the therapeutic response to ECT, or exposure to adversity.

EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2021)

Article Neurosciences

Region-Specific KCC2 Rescue by rhIGF-1 and Oxytocin in a Mouse Model of Rett Syndrome

Valentina Gigliucci, Jasper Teutsch, Marc Woodbury-Smith, Mirko Luoni, Marta Busnelli, Bice Chini, Abhishek Banerjee

Summary: The study found that Rett syndrome (RTT) is associated with deficits in KCC2 function and E/I balance. Treatment with recombinant human insulin-like growth factor-1 (rhIGF-1) and oxytocin (OXT) may restore KCC2 expression and normalize E/I balance. These findings provide new therapeutic strategies for RTT.

CEREBRAL CORTEX (2022)

Editorial Material Neurosciences

Long-term effects of early-life manipulations: risks and advantages for neurodevelopment

Valentina Gigliucci, Matteo Di Segni, Rossella Ventura, Marco Battaglia

FRONTIERS IN CELLULAR NEUROSCIENCE (2023)

Article Neurosciences

Oxytocin receptors in the Magel2 mouse model of autism: Specific region, age, sex and oxytocin treatment effects

Valentina Gigliucci, Marta Busnelli, Francesca Santini, Camilla Paolini, Alessandra Bertoni, Fabienne Schaller, Francoise Muscatelli, Bice Chini

Summary: The neurohormone oxytocin (OXT) is involved in social behavior regulation and is being investigated as a potential therapeutic option for neurodevelopmental disorders. In a mouse model of Schaaf-Yang Syndrome, OXT administration in early postnatal stages rescued autistic-like behavior and cognition. Oxytocin receptor (OXTR) levels were dysregulated in the hippocampus of adult Magel2-KO males, but normalized by OXT treatment. Further analysis showed age, genotype, and OXT treatment effects on OXTR levels in different brain regions.

FRONTIERS IN NEUROSCIENCE (2023)

Review Pharmacology & Pharmacy

Intranasal Polymeric and Lipid-Based Nanocarriers for CNS Drug Delivery

Rebecca Maher, Almudena Moreno-Borrallo, Dhruvi Jindal, Binh T. Mai, Eduardo Ruiz-Hernandez, Andrew Harkin

Summary: Nanomedicine focuses on developing nanocarriers to improve drug delivery to the brain for the treatment of neuropsychiatric disorders and neurological diseases. Polymer and lipid-based drug carriers have advantages in delivering drugs to the central nervous system (CNS) due to their safety, drug loading capacity, and controlled release properties. These carriers have shown potential in penetrating the blood-brain barrier (BBB) and have been extensively studied in glioblastoma, epilepsy, and neurodegenerative disease models. Intranasal administration has emerged as an attractive route to bypass the BBB using tailored nanocarriers. This review explores the characteristics of polymeric and lipid-based nanocarriers and their potential for CNS drug repurposing, as well as the progress in intranasal drug delivery for neurological diseases.

PHARMACEUTICS (2023)

暂无数据